Vemudx (Vemurafenib) 240mg Tablets | Laos Generic | GLT

Generic Information: Vemudx (Vemurafenib) — BigBear Pharmaceutical Laos Generic

Vemudx is a Laos-manufactured generic of vemurafenib, produced by BigBear Pharmaceutical Co., Ltd. (老挝大熊制药), a pharmaceutical manufacturer based in Laos. This page covers the 240 mg film-coated tablet supplied in a 56-tablet box. Vemudx provides the same selective BRAF V600E inhibition as the originator Zelboraf, giving patients with BRAF-mutant melanoma and Erdheim-Chester Disease a cost-effective route to this life-extending targeted therapy. Each film-coated tablet contains 240 mg of vemurafenib, matching the reference product in both strength and dosing schedule, and the product represents the expanding capability of Laos-based manufacturers to produce affordable precision oncology medicines.

What Is Vemudx (Vemurafenib) Used For?

Vemudx is used for the treatment of unresectable or metastatic melanoma in patients whose tumors carry the BRAF V600E mutation, and for Erdheim-Chester Disease with the BRAF V600 mutation. These indications mirror the originator, ensuring that patients who need a BRAF inhibitor have access to the same targeted mechanism without the prohibitive price of the branded drug. For the significant number of melanoma patients with limited financial resources, Vemudx offers a meaningful alternative that keeps the door open to molecularly guided treatment.

How Does Vemudx (Vemurafenib) Work?

Vemudx contains vemurafenib, which selectively inhibits the mutant BRAF V600E protein. In BRAF-mutant melanoma, a single mutation in the BRAF gene produces a kinase that is constitutively active, driving the MAPK signaling cascade that fuels tumor growth and survival. By blocking this hyperactive enzyme, vemurafenib interrupts the proliferative signal, leading to tumor stasis and, in many patients, regression. Treatment requires prior confirmation of the BRAF V600E mutation, and the drug is contraindicated in wild-type BRAF melanoma, where paradoxical activation could occur.

Indications

Vemudx is indicated for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation, as detected by an approved test, and for patients with Erdheim-Chester Disease with the BRAF V600 mutation. It is not indicated for wild-type BRAF melanoma.

Dosage

The recommended dose is 960 mg (four 240 mg tablets) orally twice daily, spaced roughly 12 hours apart, with or without food. A BRAF V600E mutation must be confirmed in tumor tissue before starting treatment. Tablets are taken whole with water. The treatment is continued until disease progression or unacceptable toxicity, with dose reductions or interruptions guided by the severity of adverse effects and any QT-interval prolongation.

Side Effects

The most common adverse reactions are arthralgia, rash, alopecia, fatigue, photosensitivity, nausea, pruritus, and skin papillomas. Monitoring is recommended for new primary skin malignancies, including cutaneous squamous cell carcinoma, as well as for QT prolongation, hepatotoxicity, and ocular reactions such as uveitis. Patients should undergo dermatologic assessment before and during therapy and use appropriate sun protection to reduce the risk of photosensitivity reactions.

Storage

Store Vemudx at room temperature between 20°C and 30°C, in a dry place away from moisture. Keep all medicines out of the reach of children and do not use beyond the printed expiry date.

Why Choose the GLT?

Vemudx delivers the same targeted BRAF inhibition as the originator at a price that makes long-term treatment genuinely feasible. The branded Zelboraf commands a Western list price that places a month of therapy far beyond the reach of most cash-paying patients, whereas Vemudx from BigBear Pharmaceutical offers a far more affordable Laos-manufactured alternative. For patients and institutions seeking reliable access to vemurafenib, GLT — a Hong Kong-licensed supplier — provides a verified sourcing channel with batch documentation, transparent pricing, and support throughout the ordering and delivery process.

How to Order Vemudx (Vemurafenib)

To order Vemudx, contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Please share the required quantity, your destination country, and any documentation needs so we can confirm current availability and delivery terms.

FAQ

Is Vemudx a generic of Zelboraf? Yes. Vemudx is a Laos-manufactured generic of vemurafenib, the active ingredient in the originator Zelboraf.

Who makes Vemudx? Vemudx is produced by BigBear Pharmaceutical Co., Ltd. (老挝大熊制药), based in Laos.

What is Vemudx used for? It treats unresectable or metastatic melanoma with the BRAF V600E mutation and Erdheim-Chester Disease with the BRAF V600 mutation.

Does Vemudx require BRAF testing? Yes. A confirmatory BRAF V600E test is required before treatment, and the drug must not be used in wild-type BRAF melanoma.